Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue (2018 - 2022)

Summit Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $3.2 million for Q2 2022.

  • For Q2 2022, Current Deferred Revenue fell 54.75% year-over-year to $3.2 million; the TTM value through Jun 2022 reached $3.2 million, down 54.75%, while the annual FY2021 figure was $7.9 million, 5.15% down from the prior year.
  • Current Deferred Revenue reached $3.2 million in Q2 2022 per SMMT's latest filing, down from $5.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $18.6 million in Q1 2018 to a low of $1.5 million in Q4 2019.
  • Average Current Deferred Revenue over 5 years is $7.1 million, with a median of $7.1 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 76.8% in 2019, then skyrocketed 473.06% in 2020.
  • A 5-year view of Current Deferred Revenue shows it stood at $18.6 million in 2018, then tumbled by 92.17% to $1.5 million in 2019, then surged by 473.06% to $8.4 million in 2020, then fell by 5.15% to $7.9 million in 2021, then tumbled by 59.3% to $3.2 million in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Current Deferred Revenue are $3.2 million (Q2 2022), $5.1 million (Q1 2022), and $7.9 million (Q4 2021).